市場調查報告書
商品編碼
1368672
哺乳動物細胞發酵技術市場- 按類型(中國倉鼠卵巢(CHO)、人類胚胎腎(HEK))、應用(單株抗體、重組蛋白)、最終用途(生物製藥公司、CMO 和CDMO)與預測,2023 -2032 年Mammalian Cell Fermentation Technology Market - By Type (Chinese Hamster Ovary (CHO), Human Embryonic Kidney (HEK)), Application (Monoclonal Antibodies, Recombinant Proteins), End-use (Biopharmaceutical Companies, CMOs & CDMOs) & Forecast, 2023-2032 |
受疫苗、單株抗體和治療性蛋白等生物製藥需求飆升的支持,哺乳動物細胞發酵技術產業規模預計 2023 年至 2032 年年複合成長率將達到 8.4%。對以高產量和最小污染風險為特徵的高效且可擴展的生產流程的需求推動了該技術的採用。
此外,人們越來越關注個人化醫療和再生療法。例如,2023 年 4 月,富士通和 BSC 宣布合作,以改進他們在個人化醫療和量子計算方面的研究。這個因素,加上生物加工技術的進步,包括拋棄式生物反應器和改進的細胞系,以簡化生物製品的製造,將刺激市場動態。
哺乳動物細胞發酵技術市場根據類型、應用、最終用途和地區進行分類。
重組蛋白細分市場從 2023 年到 2032 年將實現 9.3% 的年複合成長率,因為它們廣泛應用於生物製藥行業,用於各種治療、診斷和研究目的。哺乳動物細胞發酵技術提供了生產高品質重組蛋白的理想平台,因為它能夠促進翻譯後修飾,例如糖基化,這對於這些蛋白質的功能至關重要。隨著生物製藥研究的不斷多樣化和擴展,重組蛋白應用領域將蓬勃發展。
生物製藥公司領域預計 2023 年至 2032 年年複合成長率為 8%。這些公司負責開發和製造創新生物製劑,用於治療多種疾病,包括癌症、自體免疫疾病和傳染病。哺乳動物細胞發酵技術的靈活性、可擴展性和可靠性對於尋求最佳化其生產流程的生物製藥公司來說非常有價值。大規模生產生物製劑的能力,同時確保產品品質和一致性,使該技術成為這些公司的重要資源。
由於人口成長、醫療保健支出增加以及對先進療法的需求不斷成長,亞太地區哺乳動物細胞發酵技術產業規模預計 2023 年至 2032 年年複合成長率將達到 9.5%。該地區擁有許多熱衷於採用最先進技術的生物製藥公司、研究機構和合約製造組織。隨著監管途徑變得更加精簡和有利,亞太地區市場預計在不久的將來將大幅成長。
Mammalian cell fermentation technology industry size is expected to record 8.4% CAGR from 2023 to 2032 backed by the soaring demand for biopharmaceuticals, including vaccines, monoclonal antibodies, and therapeutic proteins. The need for efficient and scalable production processes, characterized by high yields and minimal contamination risks, has fueled the adoption of this technology.
Furthermore, there is growing focus on personalized medicine and regenerative therapies. For instance, in April 2023, Fujitsu and BSC announced a collaboration to improve their research on personalized medicine and quantum computing. This factor, along with the advancements in bioprocessing techniques, including single-use bioreactors and improved cell lines, for streamlining the manufacturing of biologics, will stimulate the market dynamics.
The mammalian cell fermentation technology market is classified based on type, application, end-use, and region.
The recombinant proteins segment will record 9.3% CAGR from 2023 to 2032 as they are widely employed in the biopharmaceutical industry for a myriad of therapeutic, diagnostic, and research purposes. Mammalian cell fermentation technology offers an ideal platform to produce high-quality recombinant proteins due to its ability to facilitate post-translational modifications, such as glycosylation, essential for the functionality of these proteins. The recombinant proteins application segment is poised to flourish as biopharmaceutical research continues to diversify and expand.
The biopharmaceutical companies segment is anticipated to observe 8% CAGR during 2023-2032. These companies are responsible for developing and manufacturing innovative biologics that cater to a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The flexibility, scalability, and reliability of mammalian cell fermentation technology are highly valuable to biopharmaceutical firms seeking to optimize their production processes. The ability to produce biologics on a large scale, while ensuring product quality and consistency, positions the technology as a vital resource for these companies.
Asia Pacific mammalian cell fermentation technology industry size is predicted to witness 9.5% CAGR from 2023 to 2032 driven by a growing population, increasing healthcare expenditure, and a rising demand for advanced therapeutics. The region is home to numerous biopharmaceutical companies, research institutes, and contract manufacturing organizations that are keen to incorporate state-of-the-art technologies. As regulatory pathways become more streamlined and favorable, the APAC market is expected to experience substantial growth in the near future.